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Nephropathic cystinosis is a multisystem autosomal recessive
disease caused by cystine accumulation, which is usually
treated by oral cysteamine. In order to determine long-term
effects of this therapy, we enrolled 86 adult patients
(mean age 26.7 years) diagnosed with nephropathic
cystinosis, 75 of whom received cysteamine. Therapy was
initiated at a mean age of 9.9 years with a mean duration of
17.4 years. By last follow-up, 78 patients had end-stage renal
disease (mean age 11.1 years), 62 had hypothyroidism
(mean age 13.4), 48 developed diabetes (mean age 17.1
years), and 32 had neuromuscular disorders (mean age 23.3
years). Initiating cysteamine therapy before 5 years of age
significantly decreased the incidence and delayed the onset
of end-stage renal disease, and significantly delayed the
onset of hypothyroidism, diabetes, and neuromuscular
disorders. The development of diabetes and hypothyroidism
was still significantly delayed, however, in patients in whom
therapy was initiated after 5 years of age, compared with
untreated patients. The life expectancy was significantly
improved in cysteamine-treated versus untreated patients.
Thus, cysteamine decreases and delays the onset of
complications and improves life expectancy in cystinosis.
Hence, cysteamine therapy should be introduced as early as
possible during childhood and maintained lifelong.
Kidney International (2012) 81, 179–189; doi:10.1038/ki.2011.277;
published online 7 September 2011
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Cystinosis is a rare autosomal recessive disease caused by
intracellular cystine accumulation,1 which is estimated to
occur in 1/100,000 live births.2 The CTNS causative gene
maps to chromosome 17p13 (ref. 3). More than 90 different
CTNS mutations have been described. The 57-kb deletion is
the most common mutation associated with cystinosis; it has
been detected in B75% of cystinotic patients of European
origin.4–6 The CTNS gene encodes cystinosin, which trans-
ports the cystine out of lysosomes into cytoplasm where it
is reduced to cysteine. This transport process is defective
in cystinosis, causing intralysosomal accumulation, crystal
formation, and progressive organ damage.7 This process
is attenuated in some variants of cystinosis with residual
activity.8
Nephropathic infantile cystinosis is the most common
form of the disease. Early symptoms include Fanconi’s
syndrome, rickets, impaired growth, polyuria, and polydipsia
at 6–12 months of age.9 End-stage renal disease (ESRD)
occurs at approximately 10 years of age in the absence of
treatment.10 Renal transplantation markedly improved the
life span of cystinotic patients. However, cystine accumula-
tion continued in non-renal organs.11 The clinical course of
cystinosis changed from that of a largely renal disease to a
multisystem disorder that can encompass severe corneal and
retinal damage,12 distal myopathy,13 decreased pulmonary
function,14 impairment of swallowing,15 deterioration of the
central nervous system,16 endocrinopathies,17 vascular calcifi-
cations,18 nodular regenerating hyperplasia of the liver,19
pancytopenia,20 and male hypogonadism.21
Since 1987, therapy for nephropathic cystinosis has
centered on the oral administration of cysteamine.22 When
compliance is consistent, cysteamine achieves leukocyte
cystine depletion of up to 95%. However, because of
inconvenient dosing requirements and barely tolerable side
effects, cysteamine compliance is challenging.
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Little has been known about the long-term progression of
nephropathic cystinotic patients since cysteamine treatment
became available. Gahl et al.23 have recently described the
natural history of nephropathic cystinosis in a cohort of 100
adults and demonstrated that long-term oral cysteamine
therapy mitigates the effects of the disease. Outcome of 10
Dutch cystinotic adults has been studied24 but no uniform
treatment strategy was applied. In 1995, Broyer et al.25
described a cohort of 33 cystinotic French adults, but only
five patients were under treatment. In France, in 1999, out of
144 cystinotic patients, Cochat et al.26 reported data from 115
individuals who received cysteamine, but the long-term effect
of therapy could not be analyzed. After 10 years, we studied
the clinical outcomes of a cohort of French adults with
nephropathic cystinosis and the impact of long-term oral
cysteamine administration.
RESULTS
Patient characteristics
A total of 86 adult cystinotic patients from 82 pedigrees were
included (44 male, 42 female). Twelve patients were from
consanguineous families. Mean age at diagnosis was 2.2 years
(median 1.5; range 0.5–11.6). Mean age at last follow-up was
26.7±7.0 years (median 25.9; range 15.2–50.1).
The mean age at first clinical symptoms was 11.1 months
(median 9; range 3–48). The earliest clinical symptoms were
polyuria–polydipsia for 82% of the patients, growth retarda-
tion for 63%, and rickets for 41%. All the children had
Fanconi’s syndrome. Cystine corneal deposits were described
at diagnosis in 71% of the patients.
Final adult height was 152.1 cm (range 129–177) and
142.1 cm (range 105–164) for men and women, respectively.
Growth hormone was administered to 28 patients (33%),
starting at a mean age of 10.0 years (median 10.1; range
3.6–15.6) for a mean duration of 4.3 years (median 2.7;
range 0.9–11.7). Among the 58 patients who did not
receive growth hormone, 10 individuals (17%) were
significantly shorter than the 48 patients (83%) treated with
cysteamine (mean 127.8 cm, median 129.0, range 105–150 cm
versus mean 147.6 cm, median 147.0, range 111–177;
PWilcoxono0.001).
Cysteamine therapy was administered to 75 patients (75/86,
87%), starting at a mean age of 9.9 years (median 4.3; range
0.9–38.6) with a mean duration of 17.4 years (median 18.4;
range 0.9–28.4). A total of 48 patients started cysteamine
therapy before 8 years of age, one patient started between
8 and 15 years, and 27 patients started after 15 years
(Figure 1). For the 75 treated patients, compliance was
reported as good for 26 patients (34.6%) and quite good for
31 patients (41.3%). A total of 21 patients had extended
periods without treatment (seven missing data). Mean
leukocyte cystine level recorded in 78 patients during the
overall follow-up was o2 nmol half-cystine/mg protein for
22 patients (28.2%; mean level 1.8), between 2 and 3 for 27
patients (34.6%; mean level 2.3), and 43 for 29 patients
(37.2%; mean level 4.3).
Renal function
ESRD developed in 78 patients (91%) at a mean age of 11.1
years (median 9.9; range 5.7–22.7). A total of 65 patients had
received one kidney transplant, 11 patients had received a
second kidney graft, and 2 patients had undergone three
transplants. The remaining eight patients (9%) who had
functioning native kidneys had a mean age of 21.5 years
(median 21.0; range 15.2–28.8). Of these, five, one, and
two patients, respectively, had chronic kidney disease stages
1, 3, and 4 (ref. 27).
Extrarenal complications
Hypothyroidism was diagnosed in 62 patients (71%) at
the mean age of 13.5 years (median 11.5; range 5.8–34.8).
Diabetes developed in 48 patients (55.8%) at the mean age
of 16.8 years (median 15.3; range 1.1–43.6) and occurred
within the first year post transplant in 8/48 patients (16.7%).
Neuromuscular disorders were reported in 32 patients
(37.2%) at the mean age of 23.3±6.3 years (median 25.9;
range 7.0–35.4) and were categorized as follows: myopathy in
22 patients (68.8%), swallowing impairment in 17 (53.1%),
paresis in 24 (75.0%), related to stroke in 9 patients (37.5%),
mental function deterioration in 18 (56.3%), and seizures in
10 (31.3%). Cerebral imaging was performed in 38.4% of the
patients (33/86). Of these, imaging was performed in
response to symptoms of neurological disorders in 72.7%
(24/33) of the cases, with the remaining 27.3% (9/33)
performed systematically. Of the nine patients who under-
went systematic imaging, results were normal in 33.3% of
cases (3/9) and showed cortical atrophy in the other 66.7%.
Tomodensitometry or magnetic resonance imaging per-
formed to explore neurological symptoms were normal
(13%) or showed cerebral calcifications (38%), cortical
atrophy (33%), or ischemia (25%).
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Figure 1 |The age at which end-stage renal disease (ESRD)
developed according to the age at which cysteamine therapy
was introduced. The X¼ Y line separates the patients who
started cysteamine before ESRD onset (n¼ 40), on the left, and, on
the right, the patients who started cysteamine after ESRD onset
(n¼ 27). The eight patients without ESRD are displayed with
unfilled circle with their age at last follow-up. Patients who were
never treated are displayed on the right part of the graph (n¼ 11).
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Eighteen patients (20.9%) underwent splenectomy
during the period 1975–1997. Since 1997, no splenectomy
has been performed. Hypogonadism was reported in 29.5%
of the men (13/44). None of the men had children.
Among the 42 women, 3 had children (one, one, and two
children, respectively). Only four patients (5%) experienced
pulmonary insufficiency. All patients exhibited cystine
corneal deposits causing photophobia. In total, 12 patients
(14%) had corneal erosions, 3 of whom required corneal
replacement.
Effects of cysteamine therapy
Renal complications. Patients were separated into three
groups: patients who started cysteamine therapy before
5 years of age (n¼ 40, 46.5%), after 5 years of age (n¼ 8,
9.3%), and those who were not treated before ESRD (n¼ 38,
44.2%). The characteristics of those populations are pre-
sented in Table 1. The ESRD incidence is decreased in
cysteamine-treated patients versus the absence of treatment
(Table 2). However, starting cysteamine therapy after 5 years
does not significantly decrease the incidence of ESRD in
comparison with the absence of treatment. The age at ESRD
was 13.4±4.8 years (median 12.2) and 9.6±2.6 years
(median 9.5), in the before 5-years- and after 5-years-treated
patient groups (Po0.05), respectively. Eight patients had
chronic kidney disease but did not reach ESRD. All of them
had been treated with cysteamine before 2.5 years of age
(median 1.5, Figure 1).
Kaplan–Meier survival curves indicated that starting
cysteamine therapy before the age of 5 years significantly
delayed the ESRD onset (Figure 2a, Po0.0001). When
cysteamine therapy is started after 5 years of age, ESRD is not
significantly delayed in comparison with the absence of
treatment (Figure 2a).
Renal survival was analyzed according to compliance
to cysteamine therapy and impact of leukocyte cystine level
(o3 and 43 nmol half-cystine/mg protein). Patients with
good compliance had significantly delayed ESRD in compar-
ison with patients with lower compliance or those not treated
(log-rank Po0.0001). ESRD occurred significantly later in
patients below 3 nmol half-cystine/mg protein than in
patients with higher concentrations (Figure 2b, log-rank
P¼ 0.004).
Extrarenal complications. The influence of the age at
cysteamine treatment introduction on the onset of hypothyr-
oidism, diabetes, and neuromuscular disorders was assessed
according to whether patients were treated before, after 5
years of age, or not treated before the event (Table 2). The
incidence of hypothyroidism, diabetes, and neuromuscular
disorders was significantly reduced when cysteamine was
started before 5 years of age in comparison with the absence
of treatment. Starting therapy after 5 years still decreases the
incidence of hypothyroidism and diabetes when compared
with no treatment.
Survival curves indicated that treatment started before
5 years of age was associated with significant delay, compared
with untreated patients, in the occurrence of hypothyroidism,
diabetes, and neuromuscular disorders (log-rank Po0.001,
see Figures 2c–e). For diabetes and hypothyroidism,
a statistical significant delay of the event was still noticed
between patients who started treatment after the age
of 5 years compared with the absence of treatment
(Po0.001).
The total number of events among ESRD, hypothyroid-
ism, diabetes, neuromuscular events, and death was
significantly lower in the group treated before 5 years than
in the other groups (median 2 versus 4; Po0.001, Table 1).
Only five patients (5%), with a mean age of 21.4 years
(median 20.9, range 15.7–27.2), all treated with cysteamine
before 2.5 years of age, did not develop any complications.
We analyzed the sequence of onset of complications. Figure 3
shows the age at the first complication onset according to the
age at the start of cysteamine treatment. All patients who had
the first complication after 15 years of age were treated
with cysteamine before 3 years of age. The first complica-
tion consisted in ESRD (61/81¼ 75.2%, median age 9.8
years), hypothyroidism (16/61¼ 19.8%, median age 8.7
years), diabetes (2/81¼ 2.5% median age 4.8 years), and
neuromuscular disorders (2/81¼ 2.5% median age 9.0 years).
The percentage of patients who had at least two, three,
four, and five complications were 75.6% (median age 12.4
years), 62.8% (median age 17.9 years), 37.2% (median
age 24.3 years), and 12.8% (median age 26.8 years),
respectively. The most frequent complications were,
in the chronological order, ESRD, hypothyroidism, and
diabetes.
Educational and socioprofessional outcome. Educational
level was set for each patient and categorized into the
following four groups: primary school (10.5%), middle
school (43.0%), high school (16.3%), and university
(30.2%; Table 3). The mean age at the start of cysteamine
treatment was 21.0 (median 21.4, range 7.3–33.9), 9.9
(median 4.3, range 1.2–30.4), 6.7 (median 2.6, range
0.9–24.5), and 9.1 (median 4.2, range 0.9–38.6) years,
respectively. With regard to the socioprofessional outcome,
17.4% of the patients were not professionally integrated,
39.5% were students, 31.4% were technicians, and 11.6%
were senior executives. Their mean age at cysteamine
treatment introduction was 16.7 (median 19.3, range
1.2–33.9), 4.4 (median 1.9, range 0.9–19.9), 11.8 (median
5.2, 1.4–38.6), and 14.7 (median 19.9, range 1.2–27.7) years,
respectively.
Death. Twenty-four patients died (27.9%): 29.2% (7/24)
had never been treated, 8.3% (2/24) had been treated before 5
years of age, and 62.5% (15/24) had been treated after 5 years
of age (Table 2).
Survival curves show that life expectancy is significantly
improved in the patients treated before the age of 5 years
when compared with the absence of treatment (P¼ 0.03,
Figure 2f). Starting cysteamine after 5 years of age still
significantly improves the life expectancy in comparison with
the untreated patients (Po0.05, Figure 2f).
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Causes of death were linked to cystinosis or related to
renal failure. Patients treated before 5 years of age died from
infection (n¼ 1) and neurological reasons (n¼ 1). In the
group treated after 5 years of age, death occurred because of
pulmonary edema (n¼ 2), infections (n¼ 2), neurological
reasons (n¼ 4), suicide (n¼ 1), respiratory distress due to
swallowing impairment (n¼ 4), trauma (n¼ 1), and for one
patient the cause remained unknown. The non-treated
patients died from pulmonary edema (n¼ 1), infections
(n¼ 2), digestive hemorrhage (n¼ 1), and neurological
reasons (n¼ 3).
CTNS mutation
Genetic screening data were available for 68 patients (79%).
Results showed that 66 patients were homozygous or
heterozygous for a severe CTNS mutation, as already
described.1,3,28 Among them, 28 patients were homozygous
for the 57-kb CTNS deletion, 15 patients were compound
heterozygous for that deletion and for a second mutation,
and 23 patients were homozygous or heterozygous for
another severe mutation. One patient was heterozygous
carrying one severe mutation, whereas the second mutation
could not be detected. One patient was homozygous for a
mild mutation (splice site mutation, G110V).29,30
We compared the 28 patients homozygous for the 57-kb
deletion with the other 40 patients. These two groups had
similar mean age, 26.3±6.5 (range, 15.7–39.9) and 27.4±6.7
years (range, 15.1–41.1), respectively (P¼not significant).
The mean age at the start of cysteamine treatment was 10.1
(range 1.2–30.4) years and 8.4 years (range 0.9–33.9; P¼not
significant), respectively. Patient’s survival was not different
between the two groups. Occurrence of renal and extrarenal
complications (hypothyroidism, diabetes, neuromuscular
disorders) was not significantly different.
The patient with the mild mutation reached ESRD at 13.8
years. She neither had hypothyroidism nor had diabetes.
Neuromuscular disorder set at 35.4 years of age and the
patient died at 39.4 years of age.
DISCUSSION
The analysis of this cohort of 86 adults with nephro-
pathic cystinosis shows that early treatment with cysteamine
has a positive effect on the onset of renal and extrarenal
complications.
That is a second description of a large cohort of cystinotic
patients after National Institutes of Health cohort published
by Gahl et al. in 2007 (ref. 23). A French cohort of infantile
cystinosis was described by Cochat et al.26 in 1999 as an
epidemiological study. The novelty of our study relies on the
early introduction of cysteamine and an extended follow-up
until adulthood.
Our study suggests a mortality benefit from therapy,
consistent with previous data from Gahl et al.23 Mortality
rate of cystinosis in adulthood approximates one-third and
death occurs before 30 years of age. The causes of death in
our population, which were mostly infections or eventsT
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related to neuromuscular complications, were comparable to
those identified by Gahl et al.23 and to data from the
ERA–EDTA registry.31 The causes of death have evolved
during recent decades. More than 20 years ago, patients died
from uncontrolled water and electrolyte disturbances, as well
as from uremia.26,32
Renal complications are improved by cysteamine. Cyste-
amine makes it possible to delay the occurrence of ESRD if
therapy is introduced before the age of 5 years. In untreated
patients, the mean age for ESRD is 9.6 years,10 and the speed
of renal loss is slower under treatment.33 In the study by
Cochat, patients reached ESRD at a mean age of 9.8 years,
even though 83% had received treatment,26 probably due to
the late introduction of cysteamine (7.3 years). The mean age
of ESRD in our study is 11.1 years (median 9.9). In Gahl’s
study,23 92% of the patients were kidney transplanted at
the mean age of 12.3 years. In our study, and that of Gahl
et al.,23 9% and 8% of patients, respectively, did not need
renal replacement therapy at the age of 20 years. In our
cohort, patients who did not develop ESRD started treatment
at a mean age of 1.5 years. In the study by Gahl et al.,23 the
eight non-dialyzed patients were all considered by the
authors to have been adequately treated; that is, treated for
more than 8 years.
Extrarenal complications such as hypothyroidism, diabetes,
and neuromuscular disorders are less frequent and delayed
when cysteamine has been administered before 5 years of age.
Starting therapy after 5 years of age still delays hypothyroidism
and diabetes. Gahl et al.23 reported that the incidence of
diabetes, hypothyroidism, and myopathy increased with the
duration of non-treatment and decreased with longer treat-
ment. In most studies, hypothyroidism and diabetes mellitus
have occurred in 75%34,35 and 24–50%23,35,36 of the cases,
respectively. Hypothyroidism and diabetes were the earliest
extrarenal complications to develop, as confirmed in our study.
Development of diabetes after renal transplantation is more
common in cystinotic patients than in patients transplanted
for other causes;36,37 however, cysteamine may ameliorate the
diabetogenic impact of corticosteroids by delaying the age of
renal transplantation and by a direct effect on cystine
accumulation in the b-cells. Prognosis appears to be primarily
related to neuromuscular complications. More than one-third
of the patients developed a neuromuscular event at a mean age
of 24 years. Gahl et al.23 observed a 50% incidence of
myopathy and 60% incidence of swallowing abnormalities.
In our study, cerebral calcifications were observed during
imaging in more than one-third of the patients with
neurological symptoms, and atrophy in 20% of the patients.
However, atrophy was also reported in two-thirds of the
patients with no major clinical abnormality, as observed
elsewhere.38 Hepatosplenic complications became rare with
routine use of cysteamine. In our cohort, 21% of the patients
underwent splenectomy because of portal hypertension, but
none was performed after 1997.
Lifelong cysteamine treatment should be taken in order to
prevent renal and extrarenal complications of cystinosis.T
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In the study of Gahl et al.,23 adequate treatment considered as
already substantial was fixed at 8 years of age. We showed that
a treatment started before 5 years of age decreased the
incidence of complications. Age at the start of treatment was
not mentioned in the study carried out by Gahl et al.23 In our
historical cohort, the mean age of cysteamine introduction is
9.9 years. As the course of the disease was not yet described,
cysteamine therapy was stopped at the time of renal trans-
plantation. Furthermore, when extrarenal complications were
found to be related to cystinosis, cysteamine was reintro-
duced. This may explain why only one patient from our
study started cysteamine therapy between the age of 8
and 15 years. The treatment was prescribed continuously
throughout life since 1995. Cysteamine should be introduced
before 5 years of age. However, we still recommend starting
cysteamine as early as possible after diagnosis.
The better outcome of the cystinotic patients during
the last decade could also be caused by other medical and
non-medical factors. Early recognition of cystinosis allowed
starting an adequate supportive therapy quickly. Patients
benefit from improvement of renal transplantation outcome
and progresses in diabetes medications. Cystinotic patients’
families profit by better social and psychological support.
Thus, improvement in symptomatic treatment of extrarenal
complications and outcomes following renal transplantation
has potentially contributed to higher survival.
Adherence to cysteamine treatment is poor for two
reasons. First, the pharmacokinetics of the drug imposes
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Figure 2 | Survival curves using Kaplan–Meier analysis (n¼ 86). (a) End-stage renal disease (ESRD) according to age at start of
cysteamine treatment: patients were separated into three groups whether cysteamine was introduced before or after 5 years.
The third group corresponds to the patients not treated before ESRD. (b) End-stage renal disease according to leukocyte cystine level
(o3 or 43 nmol half-cystine/mg protein). Eight missing data. (c) Onset of hypothyroidism according to the age at start of cysteamine
treatment (before or after 5 years, or not treated before hypothyroidism). (d) Onset of diabetes according to the age at start of cysteamine
treatment (before and after 5 years, or not treated before diabetes). (e) Onset of neuromuscular disorder according to the age at start
of cysteamine treatment (before or after 5 years, or not treated before neuromuscular disorder). (f) Death according to the age at start
of cysteamine treatment (before or after 5 years, or not treated). The numbers below the curves are the number of patients at risk in the risk
groups at different ages.
186 Kidney International (2012) 81, 179–189
or ig ina l a r t i c l e A Brodin-Sartorius et al.: Cysteamine therapy for nephropathic cystinosis
the need for oral dosing every 6 h. Second, side effects such as
nausea and halitosis are frequent. In the study by Cochat
et al.,26 the rate of non-adherence was estimated to be 62%.
Evaluation of the compliance to cysteamine treatment
throughout life is difficult as it changes from childhood,
when parents look after their children, to puberty, when
adherence is poor, and adulthood, when adherence is
inconstant. In our study, the leukocyte cystine level was
optimal in only 28% of the patients. Research is under way to
develop a formulation that can be taken twice daily.39
Interestingly, a recent experimental work showed that using
hematopoietic stem cells is an efficient therapy to prevent
cystine accumulation in cystinosis mice.40 This new perspec-
tive of treatment needs further studies.
Although cysteamine treatment has improved the care
and management of cystinotic patients over the past 20 years,
the disease continues to disrupt the educational and
professional life of patients. In 1999, Guest et al.41 described
the professional outcome of 36 cystinotic patients: 28% were
handicapped, 39% were students, and 33% were employed.
In our cohort, 17% were at home, 40% were students, and
43% were employed. We might expect a better professional
outcome for cystinotic patients if optimized treatment could
be achieved.
Our study has limitations. It is a retrospective study that
included patients whose diagnosis of cystinosis was made
between 1961 and 1995. There may be survivor bias,
especially for the early diagnosed patients in the 1960s.
Improvement in supportive treatment for renal and extra-
renal complications could potentially contribute to higher
survival among later patients.
In conclusion, this large series confirms the severe impact
of cystinosis, both in clinical terms and in relation to
socioprofessional outcomes. Our findings indicate that
cysteamine reduces and delays the incidence of renal and
extrarenal complications. On the basis of these results, we
recommend that cysteamine treatment should be started as
early as possible, at the time of diagnosis. Pediatric and adult
clinicians must insist on adherence to the treatment regimen.
PATIENTS AND METHODS
Patients
Adult patients, at least 15 years old, in whom nephropathic
cystinosis had been diagnosed between 1961 and 1995 in
France were included. Patient’s data were collected from
historically referent hospitals (Lyon–Herriot and Paris–Necker
Hospital). French pediatric and adult nephrologists were
asked about their patients. Study conduct complied with the
Declaration of Helsinki Principles.
Criteria for diagnosis and compliance
The diagnosis of cystinosis was based on evidence of cystine
corneal deposits and/or elevated leukocyte cystine level
43 nmol half-cystine/mg protein.42 Fanconi’s syndrome
diagnosis was based on standard clinical and biological
criteria,43 including polyuria–polydipsia, electrolyte imbal-
ance, dehydration, rickets, and growth failure. Estimated
glomerular filtration rate was calculated using the abbre-
viated Modification of Diet in Renal Disease formula44 or the
Schwartz equation.45,46
Compliance to cysteamine treatment was graded by the
physician according to the patient questioning: good, quite
good, or extended period without treatment. Leukocyte
cystine level (expressed as nanomoles of half-cystine/mg
protein, normal o0.15), measured before the cysteamine
uptake, was determined using liquid chromatography–tan-
dem mass spectroscopy (API 3000LC/MS/MS; Applied
Biosystems/MDS Sciex, Foster City, CA).47
Hypothyroidism was diagnosed if a patient was receiving
L-thyroxine replacement therapy. Diabetes mellitus was
diagnosed when the patient was receiving insulin therapy.
With regard to the neurological complications, myopathy was
defined clinically by wasting of the distal muscles of the hand.
Swallowing abnormalities were diagnosed on the basis of a
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Figure 3 | The age at first complication onset (end-stage renal
disease, hypothyroidism, diabetes, neuromuscular disorder,
or death) according to the age at cysteamine treatment start.
The X¼ Y line separates the patients who started cysteamine
before the onset of the first complication (n¼ 42), on the left, and,
on the right, the patients who started cysteamine after any
complication onset (n¼ 28). The five patients without
complications are displayed with unfilled circle with their age.
Patients who were never treated are displayed on the right part of
the graph (n¼ 11).
Table 3 | Educational level and professional status with the
age at start of cysteamine treatment
Educational level
Number of patients
(percentage)
Age at start of
treatment (in years)
Primary school 9 (11%) 21.0 [7.3–33.9]
Middle school 37 (43%) 9.9 [1.2–30.4]
High school 14 (16%) 6.7 [0.9–24.5]
University 26 (30%) 9.1 [0.9–38.6]
Professional status
None 15 (18%) 16.7 [1.2–33.9]
Student 34 (39%) 4.4 [0.9–19.9]
Technician 27 (31%) 11.8 [1.4–38.6]
Senior executive 10 (12%) 14.7 [1.2–27.7]
Number, N (percentage). Mean [range].
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detailed examination showing impairment. Paresis is char-
acterized by a partial loss of movement. Patients were
described to have mental function deterioration when they
had an obvious cognitive impairment. Hypogonadism was
reported when a substitutive hormonal treatment had to be
prescribed according to clinical examination and hormonal
analysis.
CTNS mutations
Blood samples for DNA studies were drawn after obtaining
informed consent from patients. Mutations were detected as
described elsewhere.3,5
Statistical analysis
Data were collected in an Excel data sheet and transferred
to SAS data sets. The quantitative variables were described
by mean±s.d., range (minimum, maximum), median,
and quartiles, and compared when necessary, using a
non-parametric Wilcoxon test for the overall comparison.
The qualitative variables were presented by the number of
observations and percentages. Binary variables were analyzed
by the Fischer’s exact test. If the overall test was statistically
significant, multiple comparisons were made using Hochberg
adjusted test (SAS 9.2 proc multtest option ad hoc) for
quantitative variables after data ranking and for qualitative
variables. Survival analysis was performed using Kaplan–
Meier analysis with overall log-rank testing and Bonferroni
method for two-by-two comparisons. SAS 9.2 was used for
data management and all calculations. Statistical significance
was set to 5%.
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